Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EBT (2016 - 2025)

Historic EBT for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$19.5 million.

  • Cartesian Therapeutics' EBT fell 3010.27% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 5991.61%. This contributed to the annual value of -$77.1 million for FY2024, which is 6768.59% up from last year.
  • Cartesian Therapeutics' EBT amounted to -$19.5 million in Q3 2025, which was down 3010.27% from -$20.1 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' EBT registered a high of $15.0 million during Q2 2024, and its lowest value of -$196.7 million during Q4 2023.
  • For the 5-year period, Cartesian Therapeutics' EBT averaged around -$16.5 million, with its median value being -$9.0 million (2023).
  • In the last 5 years, Cartesian Therapeutics' EBT soared by 550566.8% in 2022 and then tumbled by 360861.73% in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' EBT stood at $12.4 million in 2021, then crashed by 54.71% to $5.6 million in 2022, then plummeted by 3608.62% to -$196.7 million in 2023, then soared by 87.66% to -$24.3 million in 2024, then grew by 19.6% to -$19.5 million in 2025.
  • Its last three reported values are -$19.5 million in Q3 2025, -$20.1 million for Q2 2025, and -$19.9 million during Q1 2025.